(Albany, US) DelveInsight has launched a new report on “Alopecia Market Insights, Epidemiology and Market Forecast-2030”.
DelveInsight's "Alopecia Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Alopecia, historical and forecasted epidemiology as well as the Alopecia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the facts:
- Androgenetic alopecia in men aged 40–69 years: prevalence and risk factors,” the prevalence of vertex and full androgenic alopecia increased with age from approximately 30% (age 40–55 years) to 50% (age 65–69 years).
- According to DelveInsight, alopecia areata affects as many as 6.8 million people in the US with a lifetime risk of 2.1%. People of all ages, both sexes and all ethnic groups can develop alopecia are ata.
- As DelveInsight, the prevalence of cicatricial alopecia in the US is 7%.
Request for free sample report: https://www.delveinsight.com/sample-request/alopecia-market
Scope of the Report
- The Alopecia report covers the descriptive overview of Alopecia, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Alopecia epidemiology and Alopecia treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Alopecia are provided, along with the assessment of new therapies, which will have an impact on the current Alopecia treatment landscape
- A detailed review of Alopecia market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Alopecia market
Hair loss also known as alopecia or baldness, refers to a loss of hair from part of the head or body. Typically, at least the head is involved, and the severity of hair loss can vary from a small area to the entire body.
About one-third of women experience hair loss at some time in their lives; among postmenopausal women, as many as two-thirds suffer hair thinning or bald spots. Hair loss in women often has a greater impact than hair loss does on men, because it is less socially acceptable for them. Alopecia can severely affect a woman’s emotional well-being and quality of life.
The condition occurs when white blood cells attack the cells in hair follicles, causing them to shrink and dramatically slow down hair production. It is unknown precisely what causes the body’s immune system to target hair follicles in this way.
There are different types of alopecia varying in terms of causes, severity (how much hair falls out), patterns of hair loss, the usual age it starts and body parts affected. Most of the people have alopecia areata, which is often used as an umbrella name for a spectrum (a range) of types: areata, totalis, and universalis. Because alopecia areata is a spectrum, many people had hair loss ‘in-between’ these named points. Some people found that their alopecia changed along the spectrum over time.
The extreme forms of alopecia areata are alopecia total is, which involves the loss of all head hair, and alopecia universal is, which involves the loss of all hair from the head and the body.
The main type of hair loss in women is the same as it is men.
Request for free sample report: https://www.delveinsight.com/sample-request/alopecia-market
Some of key companies are-
- Merck Pharma Co.
- Johnson & Johnson Co.
- Samumed
- And Many Others
Name of drugs covered which are given below-
- Propecia (finasteride)
- Rogaine (Minoxidil)
- SM04554
- And Many Others
Request for free sample report: https://www.delveinsight.com/sample-request/alopecia-market
Table of Contents:
1. Key Insights
2. Executive Summary of Alopecia
3. Competitive Intelligence Analysis for Alopecia
4. Alopecia: Market Overview at a Glance
4.1. Alopecia Total Market Share (%) Distribution in 2017
4.2. Alopecia Total Market Share (%) Distribution in 2030
5. Alopecia: Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Alopecia Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Alopecia Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Epidemiology
7.4.1. Alopecia Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Alopecia Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Epidemiology
7.5.2.1. Alopecia Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Epidemiology
7.5.3.1. Alopecia Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Epidemiology
7.5.4.1. Alopecia Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Alopecia Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Epidemiology
7.5.6.1. Alopecia Epidemiology Scenario in Japan (2017-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Alopecia Treatment and Management
8.2. Alopecia Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Alopecia Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Alopecia: Seven Major Market Analysis
13.1. Key Findings
13.2. Alopecia Market Size in 7MM
13.3. Alopecia Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Alopecia Total Market Size in the United States
15.1.2. Alopecia Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Alopecia Total Market Size in Germany
15.3.2. Alopecia Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Alopecia Total Market Size in France
15.4.2. Alopecia Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Alopecia Total Market Size in Italy
15.5.2. Alopecia Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Alopecia Total Market Size in Spain
15.6.2. Alopecia Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Alopecia Total Market Size in the United Kingdom
15.7.2. Alopecia Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Alopecia Total Market Size in Japan
15.8.3. Alopecia Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Alopecia
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/alopecia-market
